Olpasiran
amgen
['cardio']
ocean(a) dose-finding trial of olpadiran, a small interfering rna, showed &gt;95% reduction in lp(a) in pts with median lp(a) approx 260 nmol/l and established cardiovascular disease. #aha22 
Physician, epidemiologist & clinical trialist: https://t.co/PuSJzZsPC6 @oxford_ndph. Lead, Good Clinical Trials Collaborative https://t.co/Do4H97gzf0. CEO https://t.co/4YkPhZtWPG